These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1050 related items for PubMed ID: 29254698

  • 1. Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities.
    Cheong JE, Sun L.
    Trends Pharmacol Sci; 2018 Mar; 39(3):307-325. PubMed ID: 29254698
    [Abstract] [Full Text] [Related]

  • 2. Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives.
    Peyraud F, Guegan JP, Bodet D, Cousin S, Bessede A, Italiano A.
    Front Immunol; 2022 Mar; 13():807271. PubMed ID: 35173722
    [Abstract] [Full Text] [Related]

  • 3. A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression.
    Klar R, Michel S, Schell M, Hinterwimmer L, Zippelius A, Jaschinski F.
    Cancer Immunol Immunother; 2020 Jan; 69(1):57-67. PubMed ID: 31802183
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis.
    Labadie BW, Bao R, Luke JJ.
    Clin Cancer Res; 2019 Mar 01; 25(5):1462-1471. PubMed ID: 30377198
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Discovery and Characterisation of Dual Inhibitors of Tryptophan 2,3-Dioxygenase (TDO2) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Using Virtual Screening.
    Sari S, Tomek P, Leung E, Reynisson J.
    Molecules; 2019 Nov 28; 24(23):. PubMed ID: 31795096
    [Abstract] [Full Text] [Related]

  • 9. The therapeutic potential of targeting tryptophan catabolism in cancer.
    Opitz CA, Somarribas Patterson LF, Mohapatra SR, Dewi DL, Sadik A, Platten M, Trump S.
    Br J Cancer; 2020 Jan 28; 122(1):30-44. PubMed ID: 31819194
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Preparation and evaluation of L- and D-5-[18F]fluorotryptophan as PET imaging probes for indoleamine and tryptophan 2,3-dioxygenases.
    Tang T, Gill HS, Ogasawara A, Tinianow JN, Vanderbilt AN, Williams SP, Hatzivassiliou G, White S, Sandoval W, DeMent K, Wong M, Marik J.
    Nucl Med Biol; 2017 Aug 28; 51():10-17. PubMed ID: 28511073
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Investigation of the aryl hydrocarbon receptor and the intrinsic tumoral component of the kynurenine pathway of tryptophan metabolism in primary brain tumors.
    Guastella AR, Michelhaugh SK, Klinger NV, Fadel HA, Kiousis S, Ali-Fehmi R, Kupsky WJ, Juhász C, Mittal S.
    J Neurooncol; 2018 Sep 28; 139(2):239-249. PubMed ID: 29667084
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Evading immunity: new enzyme implicated in cancer.
    Garber K.
    J Natl Cancer Inst; 2012 Mar 07; 104(5):349-52. PubMed ID: 22349199
    [No Abstract] [Full Text] [Related]

  • 18. Kynurenine produced by indoleamine 2,3-dioxygenase 2 exacerbates acute liver injury by carbon tetrachloride in mice.
    Hoshi M, Osawa Y, Nakamoto K, Morita N, Yamamoto Y, Ando T, Tashita C, Nabeshima T, Saito K.
    Toxicology; 2020 May 30; 438():152458. PubMed ID: 32289347
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.